Browsing: Emerging Disease > Ebola
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
The results of a new study suggest that – compared with the general population – Ebola survivors may be at a significantly increased risk of death, particularly during the first year following hospital discharge.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The outbreak of Ebola in the Democratic Republic of Congo has seen over 2612 cases and 1756 mortalities since it was first announced by the WHO on 1 August 2018. One year on we ask, what have the major milestones been of this outbreak? And where are we now; is there an end in sight?
The fourth International Health Regulations Emergency Committee meeting has concluded by declaring a Public Health Emergency of International Concern, following the recent Ebola virus disease outbreak in the Democratic Republic of the Congo.
Two years after Ebola infection, survivors exhibit specific memory T cell responses against ebolavirus, according to new research presented at ECCMID.